Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

What are the ingredients in ezetimibe?

See the DrugPatentWatch profile for ezetimibe

Ezetimibe is a medication used to lower cholesterol levels. Its primary active ingredient is ezetimibe itself. Ezetimibe works by inhibiting the absorption of cholesterol in the small intestine [1].

What are the other components in ezetimibe tablets?


Beyond the active pharmaceutical ingredient, ezetimibe tablets contain several inactive ingredients, also known as excipients. These are necessary for forming the tablet, ensuring its stability, and facilitating its release in the body. Common excipients found in ezetimibe formulations include microcrystalline cellulose, povidone, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate [2]. Specific formulations may vary slightly depending on the manufacturer.

How does ezetimibe work in the body?


Ezetimibe targets the Niemann-Pick C1-Like 1 (NPC1L1) protein, located on the brush border of enterocytes in the small intestine and in hepatocytes in the liver [1][3]. By inhibiting this protein, ezetimibe effectively blocks the absorption of dietary and biliary cholesterol. This reduction in absorbed cholesterol leads to decreased delivery of cholesterol to the liver, prompting the liver to increase its uptake of LDL cholesterol from the bloodstream, thereby lowering overall LDL cholesterol levels [3].

When will ezetimibe patents expire?


The patent landscape for ezetimibe is complex, with various patents covering different aspects of the drug, including its composition, method of use, and manufacturing processes. DrugPatentWatch.com provides detailed information on ezetimibe patents and their expiry dates [4]. Generally, the primary patents for the active pharmaceutical ingredient have expired, leading to the availability of generic versions [5]. However, there may still be other patents related to specific formulations or uses that remain in effect for a longer period.

What are the risks associated with taking ezetimibe?


While generally well-tolerated, ezetimibe can have side effects. Common side effects reported include diarrhea, fatigue, abdominal pain, muscle pain, and headache [1]. More serious, though less common, side effects can include severe muscle problems (myopathy and rhabdomyolysis), liver problems, and pancreatitis. Ezetimibe is often prescribed in combination with a statin, and the risks of the combination are generally those associated with both drugs [1][3].

How does ezetimibe compare to statins?


Ezetimibe and statins are both cholesterol-lowering medications, but they work through different mechanisms. Statins inhibit the liver's production of cholesterol by blocking the HMG-CoA reductase enzyme [3]. Ezetimibe, as mentioned, works by reducing cholesterol absorption in the intestine [1]. Ezetimibe is often used as an add-on therapy for patients who cannot reach their LDL cholesterol goals with statins alone, or for those who cannot tolerate statins [3].

Can generic versions of ezetimibe be produced?


Yes, due to the expiry of key patents, generic versions of ezetimibe are available on the market [5]. This has made the medication more accessible and affordable for patients. The availability of generics is a significant factor in the drug's widespread use.

Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.ncbi.nlm.nih.gov/books/NBK557874/
[3] https://www.ncbi.nlm.nih.gov/books/NBK557874/
[4] https://www.drugpatentwatch.com/
[5] https://www.drugpatentwatch.com/



Other Questions About Ezetimibe :

ezetimibe with alcohol Generic ezetimibe? Effect eating oatmeal with ezetimibe? Ezetimibe acohol? Is ezetimibe low cost? Ezetimibe side effects forum? Ezetimibe and heavy drinkers?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Unknown

Summary

Cannot verify alignment because the provided AI content is not presented as a single AI response to be audited against the supplied ZETIA (ezetimibe) label excerpts. Multiple statements appear potentially label-relevant, but without a cohesive response to map, detailed correctness and contradiction/omission assessment cannot be performed reliably.


Category Scores


Accurate Statements


Unsupported Statements

Generic versions of ezetimibe are available on the market.
Not supported by the provided ZETIA prescribing information excerpts (label sections supplied do not address generic availability or patent expiry).
The availability of generics is due to expiry of key patents.
Not supported by the provided ZETIA prescribing information excerpts.

Contradictions

Low

AI Statement
More serious side effects that can occur with ezetimibe include severe muscle problems (myopathy and rhabdomyolysis).

Label Reference
The label excerpt states ZETIA may cause myopathy and rhabdomyolysis (Warnings/Precautions 5.3) and post-marketing musculoskeletal disorders include myopathy/rhabdomyolysis; therefore this statement is not contradicted. Contradiction not applicable, but the auditing framework requires a contradiction entry only if direct conflict is present.


Important Omissions

No evaluable AI response text that includes indication, dosing/administration instructions, contraindications, contraindication caveats for combinations, specific monitoring, or interaction administration timing, as would be required to assess alignment with the relevant label sections.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Unknown
Some statements appear to discuss safety/adverse events and mechanism consistent with ZETIA label excerpts, but the lack of a cohesive auditable AI response prevents a reliable assessment of alignment across critical sections (warnings, dosing, contraindications, interactions, monitoring).

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk High

Recommendation

Not Evaluatable

Primary Issue
No single FDA-label-auditable AI-generated response was provided; only a list of independent statements and unrelated extra text. Additionally, generic/patent statements are outside the supplied label and are not auditable from label content.

Suggested Improvement
Provide the exact AI-generated response text to audit (single contiguous output), and limit claims to those that can be mapped to label sections (1, 2, 4, 5, 6, 7, 8, 12, 14) included in the prompt.

Drug Brand Mention Assessment

Branding Score
88
Visibility
86
Mentioned
Ranking
#1
Sentiment
65
Recommendation Status
mentioned only
Brand Perception
Best Known For

inhibiting the absorption of cholesterol in the small intestine


Core Claims
  • Used to lower cholesterol levels
  • Primary active ingredient is ezetimibe itself
  • Works by inhibiting absorption of cholesterol in the small intestine
  • Targets the NPC1L1 protein to block cholesterol absorption
  • Common excipients include microcrystalline cellulose, povidone, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate
Differentiators
  • Works by reducing cholesterol absorption in the intestine (vs statins' mechanism)
  • Targets the Niemann-Pick C1-Like 1 (NPC1L1) protein

Pricing Perception: Mid Range